Healthcare (Basel, Switzerland)

Early experiences using psilocybin therapy to support cancer patients receiving palliative care

Updated

Abstract

Essence

A palliative oncology center found that favorable views of psilocybin-assisted therapy did not translate into patient treatment during the first implementation year.

Evidence

This single-case implementation study in a Canadian tertiary care center interviewed 10 clinical and managerial stakeholders and found zero treated patients after one year, with estimated costs of CAD 2648-5827 per full intervention excluding psilocybin.

Caveat

The study reflects one institution's early implementation barriers and cost scenarios, not patient-level feasibility, safety, or effectiveness outcomes.

Simplified

Full Text

We can’t show the full text here under this license.

Funding

Competing interests

0 of 9
authors report competing interests
9 report none
PubMed

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free